Table 2:
Baseline measures of inflammation, circulating tumor cells, and circulating tumor DNA in the Exercise and Colorectal Cancer Treatment (EXACT) trial (N=57)
| Marker | Geometric mean ± SD. |
|---|---|
| High-sensitivity c-reactive protein (hsCRP) (mg/L) | 2.4 ± 2.1 |
| Interleukin-6 (IL-6) (pg/mL)a | 4.7 ± 4.0 |
| Soluble interleukin-6 receptor (sIL-6r) (pg/mL)b | 17903.9 ± 1.5 |
| Tumor necrosis factor alpha (TNFα) (pg/mL)c | 8.1 ± 1.7 |
| Soluble tumor necrosis factor alpha receptor 1 (sTNFr1) (pg/mL)d | 826.0 ± 2.0 |
| Soluble tumor necrosis factor alpha receptor 2 (sTNFr2) (pg/mL)e | 5917.5 ± 1.5 |
| Interleukin-2 (IL-2) (pg/mL)f | 3.8 ± 1.7 |
| Soluble interleukin-2 receptor alpha (sIL-2rα) (pg/mL)g | 435.8 ± 1.4 |
| Interleukin-10 (IL-10) (pg/mL)h | 24.2 ± 2.8 |
| Interleukin-23 (IL-23)(pg/mL)i | 305.1 ± 2.1 |
| Soluble receptor for advanced glycation end-products (sRAGE) (pg/mL)j | 180.2 ± 2.0 |
| Circulating tumor cells (CTCs) (cells/mL) | 1.5 ± 2.0 |
| Circulating tumor DNA (ctDNA) (%) | 0.011 ± 0.007 |
To convert pg/mL interleukin-6 to pmol/L, multiply by 0.0481
To convert pg/mL soluble interleukin-6 receptor to pmol/L, multiply by 0.0237
To convert pg/mL tumor necrosis factor alpha to pmol/L, multiply by 0.0575
To convert pg/mL soluble tumor necrosis factor alpha receptor 1 to pmol/L, multiply by 0.0182
To convert pg/mL soluble tumor necrosis factor alpha receptor 2 to pmol/L, multiply by 0.0133
To convert pg/mL interleukin-2 to pmol/L, multiply by 0.0667
To convert pg/mL soluble interleukin-2 receptor alpha to pmol/L, multiply by 0.0403
To convert pg/mL interleukin-10 to pmol/L, multiply by 0.0556
To convert pg/mL interleukin-23 to pmol/L, multiply by 0.0169
To convert pg/mL soluble receptor for advanced glycation end-products to pmol/L, multiply by 0.0294